Table 2. Covariates of Nrxn1 associated with schizophrenia in the MGS data set at P<0.001.
|
Association in human |
Mouse gene and syntenic region |
Mouse array probe ID |
Co-expression in mouse |
Mouse KO phenotype | Other human associations | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | Locus | P-value | Gene | ID | Chr | Mb | r | P(r) | GO | |||
| European Americans | ||||||||||||
| rs10140896 | 14q31.3;Intr (intronic) | 9.4E–07 | EML5 | 319670 | 12 | 100.08 | 5399699 | 0.65 | 4.7E–11 | Microtubule cytoskeleton | ||
| rs7760476 | 6p22.3;Intr | 0.00002 | ATXN1 | 20238 | 13 | 45.66 | 4622958 | −0.64 | 1.4E–10 | Addiction; cognitive function; schizophrenia; | RNA processing | |
| rs2725045 | 8p23.2;Intr | 0.00004 | CSMD1 | 94109 | 8 | 17.50 | 5613572 | 0.61 | 2.0E–09 | Addiction | ||
| rs2192420 | 14q24.3;Upstr | 0.00006 | NRXN3 | 18191 | 12 | 90.90 | 5145873 | 0.68 | 1.7E–12 | Addiction; schizophrenia | Cell adhesion | |
| rs1386688 | 8p22;Intr | 0.00007 | PSD3 | 234353 | 8 | 70.22 | 5393349 | 0.65 | 4.6E–11 | Addiction | Cell signaling | |
| rs9341356 | 6q13;Intr | 0.00007 | RIMS1 | 116837 | 1 | 22.74 | 5163292 | 0.61 | 2.4E–09 | PPI; psychotomimetic drug response; social behavior | Cognitive performance | Neuro-transmission |
| rs231150 | 8q23.3;Dwnstr | 0.0001 | TRPS1 | 83925 | 15 | 50.61 | 4317283 | 0.61 | 2.1E–09 | Transcription factor | ||
| rs17171808 | 5q31.2;Intr | 0.0002 | JMJD1B | 277250 | 18 | 34.95 | 4508461 | 0.63 | 3.5E–10 | Nuclear oxidoreductase | ||
| rs4822743 | 22q12.1;Intr | 0.0002 | TPST2 | 22022 | 5 | 112.74 | 4312446 | −0.63 | 3.0E–10 | Sulfur metabolism | ||
| rs11097407 | 4q22.2;Intr | 0.0002 | SMARCAD1 | 13990 | 6 | 65.05 | 5186186 | 0.62 | 7.9E–10 | Chromatin modification | ||
| rs2530215 | 5p15.2;Intr | 0.0003 | CTNND2 | 18163 | 15 | 30.13 | 4694831 | 0.62 | 1.3E–09 | Fear learning; cognitive deficits | Addiction; schizophrenia | Cell adhesion |
| rs11223336 | 11q25;Intr | 0.0006 | OPCML | 330908 | 9 | 27.92 | 4747785 | 0.67 | 7.5E–12 | Addiction | Cell adhesion, opioid receptor | |
| rs12448737 | 16p13.2;Intr | 0.0007 | A2BP1 | 268859 | 16 | 6.81 | 4974807 | 0.62 | 1.5E–09 | Addiction; ADHD; bipolar schizoaffective; autism | RNA processing | |
| rs17286683 | 5q31.3;Upstr | 0.0008 | ANKHD1 | 108857 | 18 | 36.79 | 4412853 | 0.61 | 3.2E–09 | Translation regulation | ||
| rs4624596 | 3q13.33;Intr | 0.0009 | GSK3B | 56637 | 16 | 38.19 | 4314494 | 0.61 | 2.2E–09 | Impaired learning; behavioral despair | Bipolar; cognitive performance | ErbB, WNT signaling |
| rs4860425 | 4q13.1;Intr | 0.0009 | LPHN3 | 319387 | 5 | 82.12 | 5370748 | 0.66 | 1.8E–11 | ADHD | Neuropeptide signaling, cell adhesion | |
| rs1536142 | 1p32.2;Intr | 0.0009 | DAB1 | 13131 | 4 | 104.29 | 4375891 | −0.63 | 5.9E–10 | Addiction | Cell adhesion | |
| African Americans | ||||||||||||
| rs13065441 | 3q26.2;Intr | 0.00002 | TNIK | 665113 | 3 | 28.56 | 4843478 | 0.68 | 2.6E–12 | Addiction; schizophrenia | WNT, MAPK signaling | |
| rs7125438 | 11q25;Intr | 0.00002 | OPCML | 330908 | 9 | 27.92 | 4747785 | 0.67 | 7.5E–12 | Addiction | Cell adhesion, opioid receptor | |
| rs409797 | 7q31.1;Intr | 0.00008 | NRCAM | 319504 | 12 | 45.67 | 5569519 | 0.64 | 1.4E–10 | PPI; social, cognitive functions | Autism | Cell adhesion |
| rs6963574 | 7q32.3;Intr | 0.00008 | MKLN1 | 27418 | 6 | 31.44 | 4419118 | 0.71 | 8.4E–14 | Cytoskeletal response | ||
| rs596929 | 11q24.2;Intr | 0.0001 | KIRREL3 | 67703 | 9 | 34.32 | 5276457 | 0.61 | 2.9E–09 | ADHD; response to antipsychotics | Cell adhesion, synapse formation | |
| rs2826771 | 21q21.1;Intr | 0.0002 | NCAM2 | 17968 | 16 | 81.51 | 5268421 | 0.63 | 4.3E–10 | Psychiatric disorders | Cell adhesion | |
| rs1351569 | 8p23.2;Intr | 0.0002 | CSMD1 | 94109 | 8 | 17.50 | 5613572 | 0.61 | 2.0E–09 | Addiction | ||
| rs17446308 | 20p12.3;Intr | 0.0002 | PLCB1 | 18795 | 2 | 134.68 | 5117797 | 0.66 | 2.2E–11 | PPI; social behavior; hyperactivity; cognitive impairment | Cognitive performance | Phospholipid metabolism |
| rs11955233 | 5q14.1;Dwnstr | 0.0003 | JMY | 57748 | 13 | 94.22 | 5373932 | 0.64 | 1.1E–10 | Cytoskeleton, transcription regulation | ||
| rs2167566 | 2p15;Intr | 0.0004 | USP34 | 17847 | 11 | 23.27 | 5362770 | 0.62 | 1.5E–09 | Protein metabolism | ||
| rs1456729 | Xp21.1;Intr | 0.0005 | DMD | 13405 | X | 81.15 | 4416174 | 0.62 | 8.7E–10 | Anxiety related | Muscular dystrophy | |
| rs13250856 | 8q11.23;Intr | 0.0005 | RB1CC1 | 12421 | 1 | 6.24 | 4969100 | 0.64 | 1.2E–10 | |||
| rs12928607 | 16p13.2;Intr | 0.0006 | A2BP1 | 268859 | 16 | 6.81 | 4974807 | 0.62 | 1.5E–09 | Addiction; ADHD; bipolar schizoaffective; autism | RNA processing | |
| rs10249419 | 7q31.2;Intr | 0.0007 | CTTNBP2 | 30785 | 6 | 18.46 | 5198380 | −0.67 | 1.2E–11 | Cytoskeleton | ||
| rs2256900 | 10q23.1;Intr | 0.0009 | NRG3 | 18183 | 14 | 39.81 | 4390722 | 0.62 | 1.3E–09 | Addiction; schizophrenia | ErbB signaling | |
| rs6460537 | 7q11.22;Intr | 0.0009 | AUTS2 | 319974 | 5 | 132.93 | 5208797 | 0.65 | 5.6E–11 | Bipolar schizoaffective | ||
Abbreviations: GO, gene ontology; KO, knockout; MAPK, mitogen-activated protein kinase; NRXN1, neurexin 1; PPI, prepulse inhibition; SNP, single-nucleotide polymorphism.